Literature DB >> 12606761

Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.

Michael Madeja1, Thorsten Leicher, Patrick Friederich, Mark A Punke, Wilhelm Haverkamp, Ulrich Musshoff, Günter Breithardt, Erwin-Josef Speckmann.   

Abstract

The effects of the antiarrhythmic drug propafenone at Kv2.1 channels were studied with wild-type and mutated channels expressed in Xenopus laevis oocytes. Propafenone decreased the Kv2.1 currents in a time- and voltage-dependent manner (decrease of the time constants of current rise, increase of block with the duration of voltage steps starting from a block of less than 19%, increase of block with the amplitude of depolarization yielding a fractional electrical distance delta of 0.11 to 0.16). Block of Kv2.1 appeared with application to the intracellular, but not the extracellular, side of membrane patches. In mutagenesis experiments, all parts of the Kv2.1 channel were successively exchanged with those of the Kv1.2 channel, which is much more sensitive to propafenone. The intracellular amino and carboxyl terminus and the intracellular linker S4-S5 reduced the blocking effect of propafenone, whereas the linker S5-S6, as well as the segment S6 of the Kv1.2 channel, abolished it to the value of the Kv1.2 channel. In the linker S5-S6, this effect could be narrowed down to two groups of amino acids (groups 372 to 374 and 383 to 384), which also affected the sensitivity to tetraethylammonium. In segment S6, several amino acids in the intracellularly directed part of the helix significantly reduced propafenone sensitivity. The results suggest that propafenone blocks the Kv2.1 channel in the open state from the intracellular side by entering the inner vestibule of the channel. These results are consistent with a direct interaction of propafenone with the lower part of the pore helix and/or residues of segment S6.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606761     DOI: 10.1124/mol.63.3.547

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Disease allele-dependent small-molecule sensitivities in blood cells from monogenic diabetes.

Authors:  Stanley Y Shaw; David M Blodgett; Maggie S Ma; Elizabeth C Westly; Paul A Clemons; Aravind Subramanian; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-23       Impact factor: 11.205

Review 2.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

3.  Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1.

Authors:  Michael Madeja; Wibke Steffen; Ivana Mesic; Bojan Garic; Boris S Zhorov
Journal:  J Biol Chem       Date:  2010-08-13       Impact factor: 5.157

4.  Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome.

Authors:  Zachary L Newman; Nicole Sirianni; Christina Mawhinney; Margaret S Lee; Stephen H Leppla; Mahtab Moayeri; Lisa M Johansen
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

5.  Effects of diltiazem and propafenone on the inactivation and recovery kinetics of fKv1.4 channel currents expressed in Xenopus oocytes.

Authors:  Dong Zhang; Shi-min Wang; Hui Chen; Xue-jun Jiang; Sheng-ping Chao
Journal:  Acta Pharmacol Sin       Date:  2011-04       Impact factor: 6.150

6.  Mechanisms of Kv2.1 channel inhibition by celecoxib--modification of gating and channel block.

Authors:  R V Frolov; V E Bondarenko; S Singh
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

7.  Regulation of antiarrhythmic drug propafenone effects on the c-type Kv1.4 potassium channel by PHo and K+.

Authors:  Zhiquan Wang; Shimin Wang; Jianjun Li; Xuejun Jiang; Neng Wang
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.